UNIGE document Scientific Article
previous document  unige:39529  next document
add to browser collection

Ostéonécrose des maxillaires et bisphosphonates

Published in Revue médicale suisse. 2005, vol. 1, no. 39, p. 2537-40,2542-3
Abstract Widely prescribed, bisphosphonates inhibit bone resorption. They are not metabolised and have long half-lives. Two cases of osteonecrosis of the jaws have recently been attributed to bisphosphonates at the University Hospital of Geneva. The recent literature reveals more than a hundred similar cases throughout the world. Bone exposure appears spontaneously or after dental care. Treatment of the osteonecrosis is controversial and cure very difficult. This pathology is usually seen in patients on chemotherapy, steroids and i.v. bisphosphonates, but is sometimes seen with low-dose p.o. bisphosphonates. In view of the strong association between bisphosphonate therapy and osteonecrosis of the jaw, specialists have recommended dental and oral evaluation during bisphosphonate therapy as well as for several years after drug discontinuation.
Keywords Age FactorsDiphosphonates/administration & dosage/adverse effects/therapeutic useDrug InteractionsHumansInfusions, IntravenousJaw/pathologyOsteonecrosis/chemically inducedSteroids/therapeutic use
PMID: 16323736
Full text
Article (Published version) (636 Kb) - document accessible for UNIGE members only Limited access to UNIGE
Research groups Groupe Lombardi Tommaso (médecine dentaire) (313)
Groupe Scolozzi Paolo (chirurgie maxillo-faciale et buccale) (896)
Groupe Desmeules Jules (pharmacologie/toxicologie) (567)
(ISO format)
JUNOD, Alain et al. Ostéonécrose des maxillaires et bisphosphonates. In: Revue médicale suisse, 2005, vol. 1, n° 39, p. 2537-40,2542-3. https://archive-ouverte.unige.ch/unige:39529

213 hits

1 download


Deposited on : 2014-08-19

Export document
Format :
Citation style :